Antakya

Researchers are evaluating the impact of basic body awareness therapy combined with lifestyle recommendations on individuals diagnosed with migraine. This study aims to assess how this therapy affects migraine-related disability, sleep quality, and quality of life. Functional status will be measured using the Migraine-Related Disability Assessment Scale MIDAS, sleep quality through the Jenkins Sleep Scale JUS, and quality of life by the Headache Impact Test before and after the treatment period. Participants will be randomly assigned to one of two groups one group will receive body awareness therapy exercises twice over an eight-week period in addition to standard treatment, while the other group will receive standard treatment alone. Standard treatment includes individual information sessions lasting about 30 minutes and educational brochures. The study is single-blinded and focuses on behavioral interventions. During the study, participants will be asked to keep a pain diary regularly for four weeks before, during, and four weeks after the training program. Assessments of functional status, sleep quality, and headache-related quality of life will be done at the start and end of the eight-week intervention. The total participation period includes the 8-week program plus the 4-week follow-up to monitor outcomes and any changes in migraine symptoms.

Researchers are evaluating how the number of rotary files used during root canal treatment affects the ability to reach the full working length in the second mesiobuccal MB2 canals of maxillary first molars and the level of pain experienced after the procedure. This randomized clinical trial compares single-file, two-file, three-file, and four-file rotary systems. The study focuses on patients needing primary endodontic treatment for maxillary first molars with pulp necrosis and asymptomatic apical periodontitis. Participants receive root canal treatments using one of four different rotary file systems. The single-file group uses the OneCurve system at 300 rpm and 2.5 Ncm torque. The two-file system applies the Perfect Minimally Invasive Kit with files used sequentially at similar speeds and torque under continuous irrigation. The three-file system employs VDW Rotate files with brushing-pecking motions, while the four-file system uses the Perfect Advanced Kit in a crown-down technique with specific rpm and torque settings. Each instrumentation step includes irrigation and cleaning to avoid debris buildup. During the study, postoperative pain is assessed daily for seven days using a visual analog scale VAS. Success in negotiating the working length in the MB2 canal is recorded during treatment. Participants are monitored for pain intensity and treatment progress, with follow-up visits to evaluate outcomes. The study runs from June 18, 2025, to September 5, 2025, with patients aged 20 to 65 years included based on specific dental health criteria.

Researchers are gathering real-world data to understand how Ruscus aculeatus L. works for adults with symptomatic chronic venous disease CVD classified as CEAP C1 to C6. This observational study focuses on evaluating the treatments effectiveness, safety, adherence, and impact on quality of life over 90 days. The study is conducted across multiple centers, following patients who receive Ruscus aculeatus L. as part of usual clinical care. Participants prescribed Ruscus aculeatus L. will be monitored for about 90 days without any additional study-required treatment or intervention. Treatment and care decisions are made by the patients doctors during routine visits. Clinical data including disease severity using the revised Venous Clinical Severity Score rVCSS, pain measured by the Visual Analog Scale VAS, quality of life assessed by the Chronic Venous Disease Quality of Life Questionnaire CIVIQ-20, adherence to treatment via the Visual Analog Scale for adherence VAS-U, and safety through adverse event reporting will be collected at baseline, Day 30, and Day 90. Participants will have routine clinic visits at these three time points where clinical assessments, questionnaires, and safety monitoring occur. Researchers aim to track changes in symptoms, pain, quality of life, and treatment adherence while observing any side effects. The total participation time spans approximately 90 days, allowing for comprehensive real-world observation of Ruscus aculeatus L. use in managing chronic venous disease.